12
Participants
Start Date
November 30, 2017
Primary Completion Date
January 31, 2019
Study Completion Date
January 31, 2019
Bemarituzumab
Administered by intravenous infusion over approximately 30 minutes
Modified FOLFOX6
"Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
Wilmont Cancer Institute, Rochester
Tennessee Cancer Specialists, Knoxville
Karmanos Cancer Institute, Detroit
The University of Arizona Cancer Center, Tucson
Innovative Clinical Research Institute, Whittier
The University of Chicago Medical Center, Chicago
Marin Cancer Care, Greenbrae
Lead Sponsor
Five Prime Therapeutics, Inc.
INDUSTRY